Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug Design.
Sabat M, Dougan DR, Knight B, Lawson JD, Scorah N, Smith CR, Taylor ER, Vu P, Wyrick C, Wang H, Balakrishna D, Hixon M, Madakamutil L, McConn D.
J Med Chem · journal article · DOI 10.1021/acs.jmedchem.1c01026